Regulatory affairs teams let drug companies down
This article was originally published in SRA
Executive Summary
Critical pharmacovigilance information that is passed on to regulatory affairs departments for processing is not always dealt with appropriately and this is leading to regulators in the UK faulting drug companies during inspections.